Ticiana A. Leal, MD, is an associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia; as well as medical director of the Clinical Trials Office and leader of the Lung Cancer Disease Team at the Winship Cancer Institute of Emory University
In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.
Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.
Key opinion leaders examine the PD-L1 expression and tissue tumor mutational burden (TMB) data from the CASPIAN trial, which evaluated the combination of durvalumab with platinum-etoposide for extensive-stage small cell lung cancer (ES-SCLC), weighing the potential predictive value of PD-L1 and tissue TMB in assessing progression-free survival (PFS) and objective response rate (ORR) outcomes.
Medical experts specializing in small cell lung cancer (SCLC) delve into the complex topic of immunotherapy resistance, exploring potential mechanisms, clinical implications, and potential strategies to overcome this challenge in the treatment of patients with SCLC.
Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.
A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.
Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.
Panel experts analyze findings from the phase 3 ADRIATIC trial, examining overall and progression-free survival data, exploring the interaction between durvalumab and concurrent chemoradiotherapy within the tumor microenvironment, and evaluating the impact of time intervals from the completion of concurrent chemoradiotherapy to the initiation of consolidation therapy with a PD-L1 inhibitor.
Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.
Ticiana Leal, MD, discusses the investigation of patritumab deruxtecan in the HERTHENA-Lung01 study in advanced EGFR-mutated non–small cell lung cancer.
Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.
Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.
Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.
Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.
Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.
A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.
Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.
Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.
Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.
Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).
Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.
Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.
Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.
Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.
Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.
Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.
Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.
Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.
Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.
